Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------|---------------------|----------------------|----------------|---------------------|------------------|-------------------|-------------------------------|-------------------------------|----------------------|-- ...

The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024.Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. Revenue from the sh ...

Core Viewpoint - Merck (MRK) is expected to report a quarterly earnings decline of 29.6% year over year, with earnings per share (EPS) projected at $1.50, while revenues are forecasted to increase by 3.7% to $16.54 billion [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 2.1% over the past 30 days, indicating a reassessment by analysts [1][2]. - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [2]. Key Metrics Forecast - Analysts predict 'Sales- Oncology- Alliance Revenue- Lynparza' at $346.03 million, reflecting a year-over-year increase of 15.7% [4]. - 'Sales- Oncology- Keytruda' is expected to reach $7.38 billion, indicating a 16.5% increase from the previous year [4]. - 'Sales- Hospital Acute Care- Zerbaxa' is forecasted at $59.30 million, showing an 11.9% year-over-year change [4]. Additional Sales Projections - 'Sales- Oncology- Alliance revenue- Lenvima' is estimated at $275.08 million, with a year-over-year change of 5.8% [5]. - 'Sales- Hospital Acute Care- Bridion - U.S.' is projected to be $309.22 million, reflecting a 16.7% increase year over year [5]. - 'Sales- Oncology- Keytruda - International' is expected to be $2.93 billion, indicating a 15.2% increase [6]. Regional Sales Insights - 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' is projected at $168.05 million, with a 9.8% year-over-year change [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - International' is expected to reach $177.98 million, reflecting a 21.9% increase [7]. - 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' is forecasted at $180.66 million, indicating a 12.9% increase [8]. - 'Sales- Hospital Acute Care- Zerbaxa - U.S.' is expected to be $32.48 million, reflecting a 12% increase year over year [9]. Stock Performance - Merck shares have decreased by 8.5% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2% [9].

There's a lot to like here.No matter how well the stock market is performing, investors can always find some companies that aren't keeping pace with broader equities. This year, pharmaceutical giant Merck (MRK -1.79%) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%.Even when we zoom out, Merck hasn't performed particularly well in recent years. The company has significantly trailed the S&P 500 over the past decade. Does that mean investors should stay away from Me ...

TROY, Mich., Oct. 25, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Merck & Co. (NYSE: MRK) as its "Stock to Study" and Ball Corp (NYSE: BALL) as its "Undervalued Stock" in the January 2025 issue for investors' informational and educational use. The organization remains concerned about the number of Americans who are investing for the future. "Too many Americans hesitate to invest, waiting for what they believe is the perfect moment, ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio, or simply access the investment bank-grade financial models and research. I hope to see you there.Merck & Co., Inc. (NYSE: MRK ) will report its Q3 earnings next Thursday, 31st October. I covered the company shortly before Q2 earnings, assigning the stock a "Hold" rati ...

Merck (MRK) will report its third-quarter earnings on Oct. 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.54 billion and $1.54 per share, respectively. Earnings estimates for Merck have declined from $8.01 to $7.80 per share over the past 30 days. For 2025, earnings estimates have declined from $9.70 to $9.64 per share over the same timeframe.Image Source: Zacks Investment ResearchEarnings Surprise History of MerckThe healthcare bellwether’s performance has been ...

Merck (MRK) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 31. On ...

Merck's (MRK) stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals industry. The stock has also underperformed the sector and the S&P 500 Index, as seen in the chart below. The stock is also trading below its 200- and 50-day moving averages. Merck Stock Underperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster PD-L1 inhibitor Keytruda being the key t ...

Gilead Sciences, Inc. (GILD) and partner Merck (MRK) announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.Data showed a treatment switch to an investigational oral once-weekly combination regimen of islatravir and lenacapavir maintained viral suppression in adults at week 48.Shares of the company have risen 6.2% year to date against the industry’s decline of 1.7%.Image Source: Zacks Investment ResearchData From GILD an ...